Various regimens are available for induction therapy for MCL. Guidelines from the National Comprehensive Cancer Network recommend that high-dose therapy be considered for patients with stage II (bulky) disease and stage III-IV disease who show a complete or partial response to induction therapy. Patients should then be considered for autologous stem cell transplant (SCT).
According to a 2015 consensus statement from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation and the European MCL Network (EBMT/EMCL), autologous SCT is recommended as the standard first-line consolidation therapy for patients who achieve a complete or partial remission after induction therapy. The EBMT/EMCL supports consideration of allogeneic SCT for patients who experience relapse after autologous SCT.
Learn more about additional MCL management considerations and recommendations.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Elwyn C. Cabebe. Fast Five Quiz: Management of Mantle Cell Lymphoma - Medscape - Nov 17, 2021.